Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-31
1999-06-01
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514252, 514253, 544357, 544370, 544373, 544384, 544390, 544391, 544399, 544400, A61K 31495, C07D295155, C07D24108, C07D40312
Patent
active
059088435
ABSTRACT:
Novel piperazine derivatives of formula I:
REFERENCES:
patent: 5084466 (1992-01-01), Alig et al.
patent: 5294616 (1994-03-01), Duggan et al.
patent: 5294713 (1994-03-01), Sugihara et al.
Born, Nature, vol. 194, No. 4832, pp. 927-929 (Jun. 9, 1962).
Roux et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 264, No. 1, pp. 501-508 (1993).
Muller et al in Receptor Data for Biological Experiments (Doods & van Meel, Editors), Chapter 20, pp. 112-117 (1991).
Bernotat-Danielowski Sabine
Gante Joachim
Juraszyk Horst
Melzer Guido
Raddatz Peter
Bernhardt Emily
Merck Patent Gesellschaft mit beschrankter Haftung
LandOfFree
Piperazine compounds as fibrinogen inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine compounds as fibrinogen inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine compounds as fibrinogen inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-955073